Tra.Hm
TRA.HM operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.
Business. TRA.HM operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
TRA.HM operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.
TRA.HM maintains a strong liquidity position with a current ratio of 2.76, indicating the company can cover its short-term liabilities more than two times over. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints despite its high cash and equivalents balance of 61.97 billion VND. The debt-to-equity ratio of 0.09 suggests a conservative capital structure, with total liabilities at 769.79 billion VND and total equity at 1.55 trillion VND.
In terms of profitability, TRA.HM generates a return on equity of 16.08% and a return on assets of 10.75%, both of which are strong indicators of efficient capital utilization and asset management. The company's operating income of 341.05 billion VND and net income of 249.65 billion VND reflect a healthy margin structure, although the gross profit of 1.42 trillion VND suggests a need to monitor cost of goods sold trends.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification data provided in the available sources. This lack of segment and geographic detail limits the ability to assess exposure to regional or product-specific risks.
TRA.HM's growth trajectory is supported by a revenue base of 2.66 trillion VND, with operating cash flow of 282.97 billion VND and free cash flow of 95.33 billion VND. While no specific growth projections are provided, the company's capital expenditure of -109.49 billion VND indicates a focus on cost management rather than expansion.
The risk assessment highlights a medium liquidity risk due to the negative net cash position after debt, despite a low dilution risk. No dilution sources are explicitly cited in the available documents, and the company's capital structure remains stable with no near-term dilution pressure.
No recent events, such as filings or transcripts, are available in the provided data to inform the company's strategic direction or operational developments.
- TRA.HM maintains a conservative capital structure with a low debt-to-equity ratio of 0.09.
- The company's return on equity of 16.08% and return on assets of 10.75% indicate strong profitability.
- Despite a high current ratio of 2.76, the negative net cash position after debt raises liquidity concerns.
- The company's revenue and segment data are not geographically or product-wise diversified, increasing concentration risk.
- No dilution sources are identified, and the risk of near-term equity issuance is low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- TRA.HM Market data — financials · 2026-05-29